{
  "success": true,
  "sourceFile": ".\\input\\Alexion_NCT04573309_Wilsons_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33
  ],
  "modelUsed": "gemini-2.5-pro",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Screened Set",
        "populationType": "Disposition",
        "instanceType": "AnalysisPopulation",
        "description": "All participants who signed an informed consent form (ICF) will be included in the Screened Set.",
        "criteria": "Signed an informed consent form"
      },
      {
        "id": "pop_2",
        "name": "Enrolled Set",
        "populationType": "Disposition",
        "instanceType": "AnalysisPopulation",
        "description": "All participants who signed an ICF and met all eligibility criteria will be included in the Enrolled Set.",
        "criteria": "Signed ICF and met all eligibility criteria"
      },
      {
        "id": "pop_3",
        "name": "Full Analysis Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "description": "The Full Analysis (FA) Set will include all participants who were enrolled and received at least 1 dose of ALXN1840. The FA Set will be the primary population for all efficacy analyses.",
        "criteria": "Enrolled and received at least 1 dose of ALXN1840"
      },
      {
        "id": "pop_4",
        "name": "Per Protocol Set",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "description": "The Per Protocol (PP) Set will include all participants in the FA Set who have no major protocol deviations that would affect the primary efficacy assessment. The PP Set will be used for sensitivity analyses of the primary efficacy endpoint.",
        "criteria": "Member of the Full Analysis Set with no major protocol deviations affecting the primary efficacy assessment"
      },
      {
        "id": "pop_5",
        "name": "Safety Set",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "description": "The Safety Set will include all participants who received at least 1 dose of ALXN1840. The Safety Set will be used for all safety analyses.",
        "criteria": "Received at least 1 dose of ALXN1840"
      },
      {
        "id": "pop_6",
        "name": "Pharmacokinetic Analysis Set",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK",
        "description": "The Pharmacokinetic (PK) Analysis Set will include all participants in the Safety Set who have sufficient plasma concentration data to allow for the derivation of at least 1 PK parameter.",
        "criteria": "Member of the Safety Set with sufficient plasma concentration data for derivation of at least 1 PK parameter"
      },
      {
        "id": "pop_7",
        "name": "Pharmacodynamic Analysis Set",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD",
        "description": "The Pharmacodynamic (PD) Analysis Set will include all participants in the Safety Set who have sufficient PD data to allow for the derivation of at least 1 PD parameter.",
        "criteria": "Member of the Safety Set with sufficient PD data for derivation of at least 1 PD parameter"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age in years, calculated from date of informed consent."
      },
      {
        "id": "char_2",
        "name": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Sex of the participant (male, female)."
      },
      {
        "id": "char_3",
        "name": "Race",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Race of the participant (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific Islander, White, or multiple)."
      },
      {
        "id": "char_4",
        "name": "Ethnicity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Ethnicity of the participant (Hispanic or Latino, Not Hispanic or Latino)."
      },
      {
        "id": "char_5",
        "name": "Height",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Height in cm at Baseline."
      },
      {
        "id": "char_6",
        "name": "Weight",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Weight in kg at Baseline."
      },
      {
        "id": "char_7",
        "name": "Body Mass Index",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Body Mass Index (BMI) in kg/m2 at Baseline."
      },
      {
        "id": "char_8",
        "name": "Time since initial WD diagnosis",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Time in years since the initial diagnosis of Wilson Disease."
      },
      {
        "id": "char_9",
        "name": "WD phenotype at diagnosis",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Wilson Disease phenotype at diagnosis (hepatic, neurologic, mixed, asymptomatic, other)."
      },
      {
        "id": "char_10",
        "name": "Baseline non-ceruloplasmin-bound-copper (NCC) concentration",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Concentration of non-ceruloplasmin-bound-copper at baseline."
      },
      {
        "id": "char_11",
        "name": "Baseline 24-hour urinary copper excretion",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "24-hour urinary copper excretion value at baseline."
      },
      {
        "id": "char_12",
        "name": "Baseline liver function tests",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline values for liver function tests such as ALT, AST, total bilirubin, albumin, and INR."
      },
      {
        "id": "char_13",
        "name": "Baseline neurological status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Neurological status at baseline, if applicable."
      },
      {
        "id": "char_14",
        "name": "Baseline psychiatric status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Psychiatric status at baseline, if applicable."
      },
      {
        "id": "char_15",
        "name": "Medical/Surgical History",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Medical and surgical history coded using MedDRA."
      },
      {
        "id": "char_16",
        "name": "Prior medications for Wilson Disease",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Prior medications used to treat Wilson Disease."
      },
      {
        "id": "char_17",
        "name": "Pretreatment copper balance",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Measurement of copper balance during the pretreatment period (Day -4 through Day -1)."
      },
      {
        "id": "char_18",
        "name": "Pretreatment molybdenum balance",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Measurement of molybdenum balance during the pretreatment period (Day -4 through Day -1)."
      }
    ],
    "summary": {
      "populationCount": 7,
      "characteristicCount": 18
    }
  }
}